Updated on 14 December 2015
Orthocell gets patent in Canada
Singapore: Regenerative medicine company, Orthocell, has been granted a patent in Canada covering the combination of bio-scaffolds and tenocytes, the cells that make up healthy tendons.
The patents are described as Canadian Patent Application No. 2685146 "Tenocyte containing bioscaffolds and treatments using the same".
The granting of these patents complements Orthocell's patent family covering cells scaffolds and combinations. This patent follows already granted patents in the USA, Singapore, China and New Zealand to provide a solid IP foundation for both cellular therapy for tendon regeneration and for the collagen based medical device Celgro.
Mr Paul Anderson, managing director, Orthocell said, "Our patent family is continuing to grow and provide us with surety around our products and product development, ensuring a solid foundation for the partnering and licencing of our technologies."
The latest patent relates to the combination of cells and scaffolds to form a regenerative construct for tendons. The patent complements Orthocell's current Ortho-ATI injectable cell therapy for degenerate tendons and collagen based soft tissue medical device Celgro.